ARS Pharmaceuticals, Inc. (SPRY) Free cash flow
- Free cash flow · 12 months (USD): Value $-196.60M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -168.14%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-196.60M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-196.41M − $197.00K ≈ $-196.60M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -168.14% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-196.60M ÷ $116.93M × 100 ≈ -168.14% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-196.41M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.91× | Operating cash flow / net income. Period ending 2026-06-30. $-196.41M ÷ $-215.43M ≈ 0.91× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -196.41M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 197.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -196.60M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 116.93M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -215.43M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-196.60M | (m) | $-196.41M | $197.00K | (m) | $116.93M | (m) | $-215.43M | (m) | (m) | -168.14% | 0.91× |
| 2026-03-31 | $-175.32M | (m) | $-175.07M | $248.00K | (m) | $98.99M | (m) | $-197.98M | (m) | (m) | -177.11% | 0.88× |
| 2025-12-31 | $-171.21M | (m) | $-170.87M | $339.00K | (m) | $84.28M | (m) | $-171.30M | (m) | (m) | -203.14% | 1.00× |
| 2025-09-30 | $-86.02M | (m) | $-85.38M | $641.00K | (m) | $142.77M | (m) | $-80.04M | (m) | (m) | -60.25% | 1.07× |
| 2025-06-30 | $-53.38M | (m) | $-52.80M | $584.00K | (m) | $112.34M | (m) | $-48.02M | (m) | (m) | -47.52% | 1.10× |
| 2025-03-31 | $-21.05M | (m) | $-20.48M | $571.00K | (m) | $97.12M | (m) | $-15.65M | (m) | (m) | -21.68% | 1.31× |
| 2024-12-31 | $12.98M | (m) | $13.55M | $563.00K | (m) | $89.15M | (m) | $8.00M | (m) | (m) | 14.57% | 1.69× |
| 2024-09-30 | $-46.03M | (m) | $-45.86M | $170.00K | (m) | $2.57M | (m) | $-49.10M | (m) | (m) | -1792.48% | 0.93× |
| 2024-06-30 | $-44.23M | (m) | $-44.16M | $73.00K | (m) | $500.00K | (m) | $-44.84M | (m) | (m) | -8846.00% | 0.98× |
| 2024-03-31 | $-53.61M | (m) | $-53.55M | $65.00K | (m) | $10.00K | (m) | $-49.70M | (m) | (m) | -536120.00% | 1.08× |
| 2023-12-31 | $-59.44M | (m) | $-59.27M | $175.00K | (m) | $30.00K | (m) | $-54.37M | (m) | (m) | -198136.67% | 1.09× |
| 2023-09-30 | $-62.75M | (m) | $-62.36M | $392.00K | (m) | $30.00K | (m) | $-61.63M | (m) | (m) | -209166.67% | 1.01× |
| 2023-06-30 | $-55.66M | (m) | $-55.28M | $379.00K | (m) | $219.00K | (m) | $-53.34M | (m) | (m) | -25413.70% | 1.04× |
| 2023-03-31 | $-45.95M | (m) | $-45.58M | $371.00K | (m) | $673.00K | (m) | $-42.39M | (m) | (m) | -6828.08% | 1.08× |
| 2022-12-31 | $-40.28M | (m) | $-40.08M | $199.00K | (m) | $1.32M | (m) | $-34.68M | (m) | (m) | -3060.56% | 1.16× |
| 2022-09-30 | $-74.01M | (m) | $-72.78M | $1.23M | (m) | (m) | (m) | $-85.38M | (m) | (m) | (m) | 0.85× |
| 2022-06-30 | $-76.57M | (m) | $-75.32M | $1.25M | (m) | (m) | (m) | $-90.17M | (m) | (m) | (m) | 0.84× |
| 2022-03-31 | $-75.97M | (m) | $-74.30M | $1.67M | (m) | (m) | (m) | $-95.24M | (m) | (m) | (m) | 0.78× |
| 2021-12-31 | $-68.13M | (m) | $-66.76M | $1.37M | (m) | (m) | (m) | $-89.48M | (m) | (m) | (m) | 0.75× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-32.11M | (m) | $-31.20M | $917.00K | (m) | (m) | (m) | $-32.95M | (m) | (m) | (m) | 0.95× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |